Cambrex and The Dow Chemical Company have entered an agreement for Cambrex to manufacture Dow’s Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for drug solubility enhancement.
 
This represents the final step in solubility partnership that Dow and Bend Research announced in October 2012 and it will help Dow to commercially supply solubility enabling excipients. Construction has begun on the new operational facility at Cambrex Karlskoga and commercial product availability is set for year-end 2013.
 
“Dow’s polymer science and application expertise, coupled with Cambrex’s capabilities positions Dow for rapid entry into the market. The AFFINISOL product platform has excellent manufacturing flexibility to match the diverse excipients needs of our customers’ pipelines,” said Bob Maughon, senior R&D director for Dow.
 
“We are proud to be part of this collaboration with Dow,” said Eric Neuffer, vice president of sales and business development for Cambrex. “This agreement between Dow and Cambrex further validates Cambrex’s commitment to finding solutions that offer our clients quality products and services to meet a market need.  This has been a great partnership with both the Dow and Cambrex teams focused on achieving project goals and objectives in a timely manner.”